Amesite (AMST) Q4 2026 earnings summary

Executive summary

• Focused on AI-powered solutions for healthcare, especially post-acute care, with NurseMagic™ and LynkMagic™ product lines driving growth and adoption in both B2B and B2C markets.

• Fiscal 2026 saw the launch of a census-based Enterprise tier, EMR compatibility, and the company's largest enterprise deployment to date.

• Strategic pivot away from academic customers to healthcare, resulting in a larger client base and reduced cash burn.

• Company continues to operate with strong fiscal discipline, prioritizing efficient resource allocation and cost management.

Financial highlights

• Revenue for the year ended June 30, 2026 was $364,777, up from $110,459 in 2025, primarily from B2B license fees for NurseMagic™.

• Net loss for FY 2026 was approximately $3,096,000, an improvement from a net loss of $3,617,000 in FY 2025.

• Cash balance as of June 30, 2026 was $2,398,809, including $100,000 in restricted cash.

• Operating expenses decreased to $3,507,883 in 2026 from $3,714,072 in 2025, driven by lower technology, content development, and marketing costs.

• No interest expense incurred; interest income declined to $47,268 due to lower cash balances.

Outlook and guidance

• Management expresses substantial doubt about the company's ability to continue as a going concern due to insufficient cash to fund operations for the next twelve months.

• Plans to generate cash through financing transactions, including potential offerings of common stock, but success is not assured and depends on market conditions.